Oral Diuretic Therapy for Ascites in Chronic Liver Disease with Portal Hypertension

Preferred Route of Administration

Oral furosemide, combined with spironolactone, is the standard of care for managing cirrhotic ascites; continuous infusion is not recommended in guideline statements. 1
Oral furosemide achieves approximately 64 % of the bioavailability of intravenous dosing in cirrhotic patients, whereas IV administration can acutely reduce glomerular filtration rate, supporting the oral route. 6

Begin therapy with furosemide 20–40 mg once daily in the morning together with spironolactone 100 mg once daily (starting range 50–100 mg for spironolactone). 1
Single‑morning dosing improves adherence and reduces nocturia. 6
Increase both agents simultaneously every 3–5 days when weight loss is <0.5 kg/day without peripheral edema or when edema persists. 1
Maintain a spironolactone‑to‑furosemide ratio of roughly 100 mg : 40 mg to preserve normokalemia. 1
Maximum approved doses are spironolactone 400 mg/day and furosemide 160 mg/day. 1
Allow at least 72 hours between adjustments of spironolactone dose because of its long half‑life. 5

Check serum potassium, sodium, creatinine, and body weight within one week of any diuretic dose change. 7
Discontinue or reduce diuretics immediately if any of the following occur:

Refractory ascites is defined as failure to achieve adequate fluid removal after ≥1 week of maximum oral diuretics (spironolactone 400 mg + furosemide 160 mg) with sodium restriction, and a mean weight loss <0.8 kg over 4 days. 1
In refractory cases, large‑volume paracentesis with albumin replacement (6–8 g albumin per litre of fluid removed) is preferred over escalation to high‑dose IV or continuous‑infusion diuretics. 1

Restrict dietary sodium to ≤2 g/day (≈88 mmol or 5 g salt) as a core component of ascites management. 1
Refer patients to a dietitian for education on sodium restriction while ensuring adequate protein (1.2–1.5 g/kg/day) and caloric intake (≥35 kcal/kg/day). 1
Fluid restriction is not required unless hyponatraemia is present. 1
Target weight loss of 0.5 kg/day without peripheral edema (up to 1 kg/day if edema is present) using clinical judgment. 1

The presence of esophageal varices does not alter the furosemide‑spironolactone dosing regimen, but it indicates clinically significant portal hypertension that warrants non‑selective beta‑blocker prophylaxis (per cirrhosis management guidelines). (guideline recommendation inferred)
Cytopenias (e.g., thrombocytopenia, leukopenia) reflect hypersplenism from portal hypertension and signal the need for closer monitoring of diuretic‑related complications. 1
Avoid overly aggressive diuresis in patients with varices, as rapid volume shifts can precipitate acute kidney injury and compromise eligibility for urgent endoscopic interventions. 1